keyword
MENU ▼
Read by QxMD icon Read
search

Soliris

keyword
https://www.readbyqxmd.com/read/27811836/recommendations-for-use-of-meningococcal-conjugate-vaccines-in-hiv-infected-persons-advisory-committee-on-immunization-practices-2016
#1
Jessica R MacNeil, Lorry G Rubin, Monica Patton, Ismael R Ortega-Sanchez, Stacey W Martin
At its June 2016 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of meningococcal conjugate vaccine (serogroups A, C, W, and Y; including MenACWY-D [Menactra, Sanofi Pasteur] or MenACWY-CRM [Menveo, GlaxoSmithKline]) for persons aged ≥2 months with human immunodeficiency virus (HIV) infection. ACIP has previously recommended routine vaccination of persons aged ≥2 months who have certain medical conditions that increase risk for meningococcal disease (1), including persons who have persistent (e...
November 4, 2016: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/27617501/c3-ch50-ratio-as-a-proposed-composite-marker-for-eculizumab-monitoring-in-atypical-hemolytic-uremic-syndrome-preliminary-results
#2
Kheir Eddine Kerboua, Fatma Haiba, Djamila Batouche
Treatment of atypical hemolytic uremic syndrome (aHUS) by the complement C5 inhibitor eculizumab (Soliris®) is highly effective but unfortunately, associated with an economic pressure on the health care systems even in high incomes countries. Despite spacing infusions has been proposed as the unique solution to minimize this economic impact, no reliable laboratory assays are available to tailor such therapy optimization. We aimed to propose and evaluate a complement composite marker for eculizumab efficacy monitoring in aHUS...
September 12, 2016: Journal of Immunoassay & Immunochemistry
https://www.readbyqxmd.com/read/27573083/recommendations-for-serogroup-b-meningococcal-vaccine-for-persons-10-years-and-older
#3
(no author information available yet)
This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy). Both vaccines are approved for use in persons 10 through 25 years of age. MenB-FHbp is licensed as a 2- or 3-dose series, and MenB-4C is licensed as a 2-dose series for all groups. Either vaccine is recommended for routine use in persons 10 years and older who are at increased risk of serogroup B meningococcal disease (category A recommendation)...
September 2016: Pediatrics
https://www.readbyqxmd.com/read/27414068/notes-from-the-field-meningococcal-disease-in-an-international-traveler-on-eculizumab-therapy-united-states-2015
#4
Allen O Applegate, Vanessa C Fong, Kara Tardivel, Susan A Lippold, Sheilah Zarate
On June 2, 2015, CDC was notified that a male airline passenger, aged 41 years, with a fever of 105.4°F, headache, nausea, photophobia, diarrhea, and vomiting, which began approximately 3 hours after departure, was arriving to San Francisco, California, on a flight from Frankfurt, Germany. His symptoms reportedly started with neck stiffness 1 day earlier. Upon arrival, the patient was immediately transported to a local hospital, where he was in septic shock, which was followed by multisystem organ failure...
2016: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/26915814/off-label-use-of-the-expensive-orphan-drug-eculizumab-in-france-2009-2013-and-the-impact-of-literature-focus-on-the-transplantation-field
#5
Johann Castañeda-Sanabria, David Hajage, Melisande Le Jouan, Anne Perozziello, Florence Tubach
PURPOSE: The orphan drug eculizumab (Soliris ®) is one of the most expensive in the world and based on expenditures is classed among the highest in France, a scenario suggestive of off-label use. Given its pharmacological properties, it is likely to be used in organ transplantation. Our purposes were to describe the consumption trends of eculizumab for off-label indications overall and in the organ transplantation field and to assess the impact of publications on the latter use. METHODS: We carried out a temporal ecological study within the French national hospitalization database (PMSI)...
June 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/26837283/the-clinical-potential-of-affibody-based-inhibitors-of-c5-for-therapeutic-complement-disruption
#6
EDITORIAL
Magnus M Berglund, Patrik Strömberg
No abstract text is available yet for this article.
2016: Expert Review of Proteomics
https://www.readbyqxmd.com/read/26034803/eculizumab-soliris-and-paroxysmal-nocturnal-haemoglobinuria-in-children-when-transfusions-are-too-frequent
#7
(no author information available yet)
Many uncertainties; assessment based on extrapolation of adult data.
May 2015: Prescrire International
https://www.readbyqxmd.com/read/25343125/current-treatment-of-atypical-hemolytic-uremic-syndrome
#8
REVIEW
Bernard S Kaplan, Rebecca L Ruebner, Joann M Spinale, Lawrence Copelovitch
Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.). Historically, aHUS was associated with very high rates of mortality and morbidity. Prior therapies included plasma therapy and/or liver transplantation. Although often life saving, these were imperfect and had many complications...
May 2014: Intractable & Rare Diseases Research
https://www.readbyqxmd.com/read/24534133/diagnosis-and-management-of-complement-mediated-thrombotic-microangiopathies
#9
REVIEW
Spero R Cataland, Haifeng M Wu
Historically, attempts were made to differentiate acquired thrombotic thrombocytopenic purpura (TTP) from atypical hemolytic uremic syndrome (aHUS) based upon the age at presentation and the presence of neurologic or renal injury. Although these means of differentiating acquired TTP from aHUS have now been demonstrated to be inaccurate, there were no clinical consequences as the treatment for both disorders remained plasma exchange therapy (PEX). With the regulatory approval and remarkable efficacy of eculizumab (Soliris) for the treatment of aHUS, the accurate and timely differentiation of acquired TTP from aHUS now has real clinical consequences...
March 2014: Blood Reviews
https://www.readbyqxmd.com/read/24331206/learnings-from-over-25-years-of-pnh-experience-the-era-of-targeted-complement-inhibition
#10
REVIEW
Ellen Heitlinger
Paroxysmal nocturnal haemoglobinuria (PNH) is a progressive and life-threatening disease that causes thrombosis, end organ damage and impaired quality of life. Chronic uncontrolled complement activation leads to chronic haemolysis, causing progressive morbidities and early mortality. Hence, early diagnosis is essential for improved patient management and prognosis. Eculizumab (SOLIRIS®) specifically inhibits chronic, uncontrolled complement activation and is the first-in-class, humanised, monoclonal antibody targeting C5 within the terminal complement pathway...
December 2013: Blood Reviews
https://www.readbyqxmd.com/read/24249647/eculizumab-a-review-of-its-use-in-atypical-haemolytic-uraemic-syndrome
#11
REVIEW
Gillian M Keating
The recombinant humanized monoclonal antibody eculizumab (Soliris(®)) is a complement inhibitor that is indicated for use in the treatment of atypical haemolytic uraemic syndrome (aHUS). This article reviews the clinical efficacy and tolerability of eculizumab in the treatment of patients with aHUS, as well as summarizing its pharmacological properties. Intravenous eculizumab inhibited complement-mediated thrombotic microangiopathy in patients aged ≥12 years with aHUS, according to the results of two noncomparative, multinational, 26-week, phase II trials...
December 2013: Drugs
https://www.readbyqxmd.com/read/23917586/perisurgical-induction-of-eculizumab-in-a-patient-with-paroxysmal-nocturnal-hemoglobinuria-its-inhibition-of-surgery-triggered-hemolysis-and-the-consequence-of-subsequent-discontinuation
#12
Naoki Kurita, Naoshi Obara, Kuniyoshi Fukuda, Hidekazu Nishikii, Shoko Sato, Satoshi Inagawa, Tomohiro Kurokawa, Yohei Owada, Haruhiko Ninomiya, Shigeru Chiba
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement (C')-induced lysis of PNH red blood cells (RBCs), which are deficient in the expression of CD55 and CD59. Surgery is one of the major clinical situations that trigger hemolytic attack and thrombosis in PNH. We describe here a case of 64-year-old man with classic PNH complicated by early-stage gastric cancer requiring distal gastrectomy under general anesthesia. We administered humanized monoclonal anti-C5 antibody (eculizumab; Soliris) for a limited period (600 mg, once a week × four times) perisurgically...
September 2013: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/23456264/successful-anticoagulant-therapy-for-two-pregnant-pnh-patients-and-prospects-for-the-eculizumab-era
#13
REVIEW
Yasuyoshi Morita, Jun-ichi Nishimura, Takahiro Shimada, Hirokazu Tanaka, Kentaro Serizawa, Yasuhiro Taniguchi, Mitsuhiro Tsuritani, Yuzuru Kanakura, Itaru Matsumura
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired stem cell disorder characterized by intravascular hemolysis and thrombosis. The most serious complication is thrombosis, the risk of which is augmented by the hyper-coagulable state that occurs during pregnancy; despite this risk, however, young female PNH patients often desire to have a baby. We recently experienced two successful deliveries in PNH patients, who were treated with anticoagulant therapy during their pregnancies. Meanwhile, given the potential benefit of eculizumab (Soliris), a humanized monoclonal antibody against C5, in reducing thrombosis and hemolysis, it represents a promising therapeutic option for the treatment of pregnant PNH patients in combination with, or in replacement of, anticoagulant therapy...
April 2013: International Journal of Hematology
https://www.readbyqxmd.com/read/22350448/eculizumab-a-guide-to-its-use-in-paroxysmal-nocturnal-hemoglobinuria
#14
Gillian M Keating, Katherine A Lyseng-Williamson, Kate McKeage
The targeted terminal complement inhibitor eculizumab (Soliris) reduces intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as stabilizing hemoglobin levels, improving fatigue and health-related quality of life, and reducing the requirement for packed red cell transfusions. Eculizumab is generally well tolerated in patients with PNH, although the risk of Neisseria meningitidis infection is increased with eculizumab, meaning that patients must be vaccinated.
April 1, 2012: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/21693335/eculizumab-for-the-treatment-of-de-novo-thrombotic-microangiopathy-post-simultaneous-pancreas-kidney-transplantation-a-case-report
#15
S Chandran, L Baxter-Lowe, J L Olson, S J Tomlanovich, A Webber
A 34-year-old female recipient of a simultaneous pancreas-kidney transplant presented 7 days posttransplant with acute renal allograft dysfunction, thrombocytopenia, and microangiopathic hemolytic anemia. Renal biopsy revealed acute antibody-mediated rejection (AMR) and acute thrombotic microangiopathy (TMA). Clinical and laboratory manifestations, which had only partly responded to treatment with daily plasma exchange and intravenous immunoglobulin, resolved rapidly and completely to eculizumab (Soliris, Alexion Pharmaceuticals, Inc...
June 2011: Transplantation Proceedings
https://www.readbyqxmd.com/read/21692905/an-open-label-clinical-trial-of-complement-inhibition-in-multifocal-motor-neuropathy
#16
Amanda M Fitzpatrick, Cameron A Mann, Sarah Barry, Katie Brennan, James R Overell, Hugh J Willison
Human and animal studies on antibody-mediated neuropathy implicate complement in pathogenesis. In animal models complement inhibition is therapeutically beneficial. The monoclonal antibody, eculizumab (Soliris™, Alexion Pharmaceuticals, Cheshire, CT), prevents cleavage of C5 and thus inhibits terminal complement activation. In an open label study, 13 multifocal motor neuropathy patients received eculizumab for 14 weeks, 10 of whom were concomitantly receiving intravenous immunoglobulin. The primary outcome was safety of eculizumab, and the secondary outcomes included change in intravenous immunoglobulin (IVIg) dosing frequency, performance, and electrophysiological parameters...
June 2011: Journal of the Peripheral Nervous System: JPNS
https://www.readbyqxmd.com/read/21253430/the-use-of-the-complement-inhibitor-eculizumab-soliris%C3%A2-for-treating-korean-patients-with-paroxysmal-nocturnal-hemoglobinuria
#17
Jin Seok Kim, Jong Wook Lee, Byoung Kook Kim, Je-Hwan Lee, Jooseop Chung
BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized by chronic complement-mediated hemolysis. Eculizumab, a humanized monoclonal antibody against the terminal complement protein C5, potently reduces chronic intravascular hemolysis. We tested the clinical efficacy and safety of a 24-week treatment with eculizumab in 6 Korean patients with PNH. METHODS: We enrolled 6 patients with PNH who had clinically significant hemolysis...
December 2010: Korean Journal of Hematology
https://www.readbyqxmd.com/read/18784156/fda-report-eculizumab-soliris-for-the-treatment-of-patients-with-paroxysmal-nocturnal-hemoglobinuria
#18
RANDOMIZED CONTROLLED TRIAL
Andrew Dmytrijuk, Kathy Robie-Suh, Martin H Cohen, Dwaine Rieves, Karen Weiss, Richard Pazdur
On March 16, 2007, eculizumab (Soliris; Alexion Pharmaceuticals, Inc. Cheshire, CT), a humanized monoclonal antibody that binds to the human C5 complement protein, received accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Eculizumab was studied in a randomized, double-blind, placebo-controlled clinical trial in 87 RBC transfusion-dependent adult PNH patients and in a supportive single-arm study in 96 patients...
September 2008: Oncologist
https://www.readbyqxmd.com/read/17989689/complement-targeted-therapeutics
#19
REVIEW
Daniel Ricklin, John D Lambris
The complement system is a central component of innate immunity and bridges the innate to the adaptive immune response. However, it can also turn its destructive capabilities against host cells and is involved in numerous diseases and pathological conditions. Modulation of the complement system has been recognized as a promising strategy in drug discovery, and a large number of therapeutic modalities have been developed. However, successful marketing of complement-targeted drugs has proved to be more difficult than initially expected, and many strategies have been discontinued...
November 2007: Nature Biotechnology
https://www.readbyqxmd.com/read/17989688/discovery-and-development-of-the-complement-inhibitor-eculizumab-for-the-treatment-of-paroxysmal-nocturnal-hemoglobinuria
#20
Russell P Rother, Scott A Rollins, Christopher F Mojcik, Robert A Brodsky, Leonard Bell
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery...
November 2007: Nature Biotechnology
keyword
keyword
16036
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"